Edition:
United States

Compugen Ltd (CGEN.OQ)

CGEN.OQ on NASDAQ Stock Exchange Global Market

2.80USD
15 Dec 2017
Change (% chg)

$0.30 (+12.00%)
Prev Close
$2.50
Open
$2.50
Day's High
$2.85
Day's Low
$2.50
Volume
949,427
Avg. Vol
31,008
52-wk High
$6.05
52-wk Low
$2.25

Chart for

About

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage... (more)

Overall

Beta: 0.53
Market Cap(Mil.): $128.50
Shares Outstanding(Mil.): 51.13
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-COMPUGEN REPORTS Q3 LOSS PER SHARE $0.19

* ‍AS OF SEPTEMBER 30, 2017, CASH AND CASH RELATED ACCOUNTS TOTALED $38.5 MILLION, COMPARED WITH $61.5 MILLION AS OF DECEMBER 31, 2016​ Source text for Eikon: Further company coverage:

Nov 07 2017

BRIEF-Compugen to initiate manufacturing of COM902

* Compugen Ltd - ‍advancing COM902 into manufacturing in anticipation of filing an investigational new drug (IND) application in 2019​

Nov 06 2017

BRIEF-Compugen appoints Paul Sekhri as new board chairman

* Compugen welcomes paul sekhri as its new chairman of the board

Aug 02 2017

BRIEF-Compugen Q2 loss per share $0.18

* Compugen ltd - ‍names paul sekhri as chairman of board effective october 2, 2017​

Aug 02 2017

BRIEF-Compugen discloses updates to collaborative activities with Bayer in immuno-oncology

* Compugen discloses updates to collaborative activities with bayer in immuno-oncology

Jul 26 2017

BRIEF-Compugen announces issuance of U.S. patent for COM701, its lead immuno-oncology product candidate

* Compugen Ltd - patent is expected to expire no earlier than February 2036 in U.S. for issued claims Source text for Eikon: Further company coverage:

Jul 25 2017

Competitors

Earnings vs. Estimates